DD106643A1 - - Google Patents
Info
- Publication number
- DD106643A1 DD106643A1 DD17394873A DD17394873A DD106643A1 DD 106643 A1 DD106643 A1 DD 106643A1 DD 17394873 A DD17394873 A DD 17394873A DD 17394873 A DD17394873 A DD 17394873A DD 106643 A1 DD106643 A1 DD 106643A1
- Authority
- DD
- German Democratic Republic
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD17394873A DD106643A1 (de) | 1973-07-12 | 1973-07-12 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD17394873A DD106643A1 (de) | 1973-07-12 | 1973-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD106643A1 true DD106643A1 (de) | 1974-06-20 |
Family
ID=5493031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD17394873A DD106643A1 (de) | 1973-07-12 | 1973-07-12 |
Country Status (1)
| Country | Link |
|---|---|
| DD (1) | DD106643A1 (de) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0537608A2 (de) * | 1991-10-11 | 1993-04-21 | APOGEPHA ARZNEIMITTEL GmbH | Verfahren zur technischen Herstellung von 2,2-Diphenyl-2-(2-ethyl-butoxy)-essigsäure-(2-dimethylamino-ethyl)-ester-hydrochlorid |
| WO2009120277A1 (en) | 2008-03-27 | 2009-10-01 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2011114195A1 (en) | 2010-03-15 | 2011-09-22 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| WO2011137054A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| WO2014025569A1 (en) | 2012-08-09 | 2014-02-13 | Chase Pharmaceuticals Corporation | Piperidinium quaternary salts |
| WO2017026950A1 (en) | 2015-08-07 | 2017-02-16 | Santa Farma Ilac San. A. S. | Controlled release propiverine formulations |
| WO2020101586A1 (en) | 2018-11-16 | 2020-05-22 | Santa Farma İlaç Sanayi̇ A.Ş. | Controlled release propiverine formulations |
| WO2022115056A1 (en) | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Sustained release formulation compositions comprising propiverine |
| EP4035668A1 (de) | 2012-09-05 | 2022-08-03 | Chase Pharmaceuticals Corporation | Neuroprotektive anticholinergische zusammensetzung und verfahren |
-
1973
- 1973-07-12 DD DD17394873A patent/DD106643A1/xx unknown
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0537608A3 (en) * | 1991-10-11 | 1993-06-16 | Apogepha Arzneimittel Gmbh | Process for the technical preparation of 2,2-diphenyl-2-(2-ethylbutoxy)acetic acid, 2-dimethylamino-ethyl ester |
| EP0537608A2 (de) * | 1991-10-11 | 1993-04-21 | APOGEPHA ARZNEIMITTEL GmbH | Verfahren zur technischen Herstellung von 2,2-Diphenyl-2-(2-ethyl-butoxy)-essigsäure-(2-dimethylamino-ethyl)-ester-hydrochlorid |
| EP3178477A1 (de) | 2008-03-27 | 2017-06-14 | Chase Pharmaceuticals Corporation | Kombination von nspacha (periphärem anticholinergen wirkstoff) wie solifenacin und einem achei (acetylcholinesterase inhibitor) wie donepezil in der verwendung zur behandlung von demenz |
| WO2009120277A1 (en) | 2008-03-27 | 2009-10-01 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| EP4088717A1 (de) | 2008-03-27 | 2022-11-16 | Chase Pharmaceuticals Corporation | Kombination aus einem nspacha (peripheres anticholinergikum) wie solifenacin und einem achei (acetylcholinesteraseinhibitor) wie donepezil zur behandlung von demenz |
| WO2011114195A1 (en) | 2010-03-15 | 2011-09-22 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| WO2011137054A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| CN104603108A (zh) * | 2012-08-09 | 2015-05-06 | 才思制药公司 | 哌啶鎓季盐 |
| US9896416B2 (en) * | 2012-08-09 | 2018-02-20 | Chase Parmaceuticals Corporation | Piperidinium quaternary salts |
| WO2014025569A1 (en) | 2012-08-09 | 2014-02-13 | Chase Pharmaceuticals Corporation | Piperidinium quaternary salts |
| EP4035668A1 (de) | 2012-09-05 | 2022-08-03 | Chase Pharmaceuticals Corporation | Neuroprotektive anticholinergische zusammensetzung und verfahren |
| WO2017026950A1 (en) | 2015-08-07 | 2017-02-16 | Santa Farma Ilac San. A. S. | Controlled release propiverine formulations |
| WO2020101586A1 (en) | 2018-11-16 | 2020-05-22 | Santa Farma İlaç Sanayi̇ A.Ş. | Controlled release propiverine formulations |
| WO2022115056A1 (en) | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Sustained release formulation compositions comprising propiverine |